The NOBLE Study

This Phase 2, multi-center, randomized, double blind, placebo-controlled, parallel group study aims to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer’s disease.

The study drug is called T-817MA, a neuroprotective agent.

You may be eligible for the study if you:

Are 55-85 years old
Have a diagnosis of Alzheimer’s disease
Are receiving treatment with Aricept® or donepezil
Have a caregiver who can accompany you for the study visits

What happens during the study?

A telephone screening will be conducted to determine if you are eligible to come in for an in-person screening visit. The in-person screening visit consists of blood work, vitals, cognitive testing, and a MRI or CT scan to determine eligibility.

If you are eligible, you will be enrolled in the study and will receive either the study drug T-817MA or placebo by mouth every 4 weeks for the first 12 weeks, then every 6 weeks, over a total period of approximately 14 months.

You will have tests of memory to assess the effects of the study drug, along with EKGs and blood work to assess for drug safety.

Where is this study taking place?

Boston University Medical Center

Meet the team

Robert A. Stern, PhD – Principal Investigator
Wendy Qiu, MD, PhD – Study Physician
Jesse Mez, MD – Study Physcian
Jane Mwicigi, MPH – Study Coordinator
Diane Essis– Recruitment Coordinator
Meenakshi Chivukula – Research Assistant

More information

Please call 617-414-1077 or email JoinADC@bu.edu for more information and to participate.

Sponsor – Toyama Chemical Co., Ltd.
Coordinating center – Alzheimer’s Disease Cooperative Study
Study website – The NOBLE Study